Pazopanib + Vinorelbine in Non Small Cell Lung Cancer (NSCLC) and Breast Cancer
Status:
Terminated
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the highest dose of Vinorelbine and Pazopanib that
can be given together without causing severe side effects. Also, this study will evaluate
what effects (good and bad) that the treatment has on patients and their cancer.